-transparent.png){kind=logo}
Pristane is known to induce a distinct type of B-cell-derived malignant lymphoma, plasmacytoma, after administration into the peritoneal cavity of genetically susceptible BALB/cAnPt mice. Since the mechanism of pristane-induced plasmacytoma development is poorly understood, we chose to examine the possibility that pristane is mutagenic in rodent cells and decided to use bacteriophage lambda-derived lacI/lacZ genes as target/reporter to quantitate mutagenesis. Here we show that in vitro exposure to micromolar amounts of pristane, delivered as an inclusion complex with beta-cyclodextrin, resulted in 1.7-fold and 6.2-fold increases of mutant frequencies over controls in a cell line of rat fibroblasts and primary mouse B lymphocytes, respectively. We conclude that pristane can be mutagenic to mammalian cells, yet are currently unable to explain the mechanism of mutagenicity. It is suggested that B-cell mutagenesis contributes to the plasmacytomagenic activity of pristane in vivo.
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
June 1995,
Cancer biochemistry biophysics,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
January 1988,
Archiv fur Geschwulstforschung,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
June 1969,
Nature,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
August 1974,
Biochimica et biophysica acta,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
March 1980,
Cancer research,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
April 1994,
Cancer biochemistry biophysics,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
December 1991,
Biochimica et biophysica acta,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
December 1994,
Molecular carcinogenesis,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
January 1987,
Experimental pathology,
K Felix, and
M Potter, and
G W Bornkamm, and
S Janz
January 2005,
Journal of biotechnology,
